Key Highlights

  • Shares of SkinHealth Systems (NASDAQ:SKIN) reached USD 14.53 on Friday, November 6, 2026, a 40.39% advance that followed third-quarter results and implied a prior level near USD 10.35 (calculated).
  • Quarterly net sales slipped 2.1% to USD 69.2 million from USD 70.7 million, and the loss shrank to USD 0.9 million, compared with USD 11.0 million previously.
  • Adjusted EBITDA climbed to USD 13.4 million, equal to a 19.3% margin, versus USD 8.9 million or 12.6% a year earlier; full-year net sales are guided between USD 281 million and USD 287 million.
  • Cash and restricted cash dropped from roughly USD 233 million at the end of 2025 to about USD 112 million, after USD 103.2 million of 2026 notes were paid off on September 30.

Third-Quarter Loss Narrows as Adjusted EBITDA Improves

SkinHealth Systems (NASDAQ:SKIN), formerly The Beauty Health Company, issued its quarterly figures on November 5, 2026, after trading hours. Net sales came in at USD 69.2 million, a 2.1% decline, as delivery system shipments dropped to 798 units from 875. Compared with USD 11.0 million twelve months earlier, the loss contracted to USD 0.9 million, and adjusted EBITDA came in at USD 13.4 million. The company markets Hydrafacial and other medical aesthetics devices and consumables. The shares were up 40.39% at USD 14.53 the following session, but the release itself does not explain that reaction, so any link to the results is an inference from timing.

Guidance Reset, a 1-for-20 Split and Share Count Math

Management set 2026 targets of USD 281 million to USD 287 million in net sales and USD 48 million to USD 50 million in adjusted EBITDA. The release gives no earlier range, so a raise cannot be confirmed. Class A shares were reverse-split 1-for-20 effective October 14, 2026, leaving about 6.5 million outstanding versus roughly 130.3 million before, a step aimed at restoring compliance with the Nasdaq USD 1.00 minimum bid rule. At USD 14.53 and using the October 7 count, the company's Equity value comes to near USD 94 million (calculated). Net sales in the prior quarter were USD 72.1 million, a 7.79% shortfall year over year.

Cash Halved After Note Repayments, With Secured Debt Still Outstanding

Cash, equivalents and restricted cash now total roughly USD 112 million, against about USD 233 million at December 31, 2025, following the September 30 repayment of USD 103.2 million in 2026 notes. Convertible senior notes of USD 243.0 million stay on the books, including 7.95% secured notes due November 15, 2028. Australia, New Zealand and China shifted to distributor partners under management's plan, SkinStylus reached six European markets, and a proposed settlement of a securities class action was disclosed. Shrinking unit sales, Leverage and a sharply smaller post-split share count could keep the stock volatile.

Where Things Stand

Partly. The 40.39% advance in SkinHealth Systems (NASDAQ:SKIN) coincides with a narrower loss and stronger adjusted EBITDA, though no company statement links the two. Net sales are still shrinking, cash has roughly halved after debt repayment, and the roughly 6.5 million shares left after the reverse split leave room for large swings in either direction. No explanation for the share move appears in the release, leaving the timing link as an inference. Watch the fourth-quarter unit shipments, how the class action settlement is structured and whether guidance moves again.